DM
PBYI icon

Deerfield Management’s Puma Biotechnology PBYI Stock Holding History

Deerfield Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-104,000
Closed -$9.09M – 98
2017
Q2 		$9.09M Buy
+104,000
New +$5.82M 0.48% 59

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management's PBYI Position: Q3 2021 in Review

Deerfield Management sold out of Puma Biotechnology (PBYI) in Q3 2021, closing a stake of 3,769,795 shares — an estimated $34.6M sold.

Deerfield Management first reported a position in PBYI in Q4 2019 and held it in 6 quarters. The position peaked at $40.6M in Q4 2020. 115 funds tracked by Wall St. Rank hold PBYI as of Q3 2021.

  • Deerfield Management reported no remaining Puma Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Deerfield Management sold 3,769,795 Puma Biotechnology shares in Q3 2021, an estimated $34.6M.
  • Deerfield Management first reported a position in Puma Biotechnology in Q4 2019 and held it in 6 quarters.
  • Deerfield Management's Puma Biotechnology position peaked at $40.6M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2021.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.